H e p a t o l o g y 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 110 Mitsui T, Iwano K, Masuko K, et al. Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology 1992;16:1109–14. Sodeyama T, Kiyosawa K, Urushihara A, et al. Detection of hepatitis C virus markers and hepatitis C virus genomic-RNA after needlestick accidents. Arch Intern Med 1993;153:1565–72. Baldo V, Floreani A, Dal Vecchio L, et al. Occupational risk of blood-borne viruses in healthcare workers: a 5-year surveillance program. Infect Control Hosp Epidemiol 2002;23:325–7. Jagger J, Puro V, De Carli G. Occupational transmission of hepatitis C virus. JAMA 2002;288:1469. Yazdanpanah Y, De Carli G, Migueres B, et al. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case– control study. Clin Infect Dis 2005;41:1423–30. Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908–14. Beld M, Penning M, McMorrow M, et al. Different hepatitis C virus (HCV) RNA load profiles following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine aminotransferase levels. J Clin Microbiol 1998;36:872–7. Gold RG, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996. Kamal SM, Moustafa KN, Chen J, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006;43:923–31. San Miguel R, Mar J, Cabases JM, et al. Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon. Aliment Pharmacol Ther 2003;17:765–73. Courouce AM, Pillonel J. Transfusion-transmitted viral infections. Retrovirus and Viral Hepatitis Working Groups of the French Society of Blood Transfusion. N Engl J Med 1996;335:1609–10. Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334:1685–90. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41–52. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. Mosley JW, Operskalski EA, Tobler LH, et al. Viral and host factors in early hepatitis C virus infection. Hepatology 2005;42:86–92. National Institutes of Health. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997;26(suppl 1):2S–10S. Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991;325:98–104. Colin C, Lanoir D, Touzet S, et al. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 2001;8:87–95. Hennig H, Schlenke P, Kirchner H, et al. Evaluation of newly developed microparticle enzyme immunoassays for the detection of HCV antibodies. J Virol Methods 2000;84:181–90. Lavanchy D, Steinmann J, Moritz A, et al. Evaluation of a new automated third- generation anti-HCV enzyme immunoassay. J Clin Lab Anal 1996;10:269–76. Lefrere JJ, Roudot-Thoraval F, Lunel F, et al. Expertise of French laboratories in detection, genotyping, and quantification of hepatitis C virus RNA in serum. J Clin Microbiol 2004;42:2027–30. Yano E, Tagawa K, Yamaoka K, et al. Test validity of periodic liver function tests in a population of Japanese male bank employees. J Clin Epidemiol 2001;54:945–51. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452–7. Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006;130:632–8. Rodger AJ, Jolley D, Thompson SC, et al. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999;30:1299–301. Thein HH, Krahn M, Kaldor JM, et al. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol 2005;100:643–51. Mark DB. Clinical and economic lessons from studies of coronary thrombolysis. J Vasc Interv Radiol 1995;6:94S–101S. World Health Organization. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: WHO, 2001. Gut 2009;58:105–110. doi:10.1136/gut.2007.145516